Novo Nordisk shares rise after Wegovy gets FDA approval for liver disease

Shares in Novo Nordisk NOVOb.CO rise around 3% after FDA granted its weight-loss drug Wegovy an accelerated approval for treatment of the liver condition MASH

"The size of the Danish market reaction will depend on how much of the US increase proves to be 'lasting'," Nordnet analyst Per Hansen says

Novo is currently the only GLP-1 product with this marketing authorisation in U.S., but Eli Lilly LLY.N is likely to start production for a similar indication, he adds

"It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market", Hansen says

Based on results from part one of the trial, Novo has applied this year for approval in Europe and Japan

Further results from part two of the trial are expected in 2029

*Novo Nordisk shares lost 46% YTD until the previous session's close